Eviana Health Corporation produces and sells cannabinoid products from natural hemp strains of cannabis sativa for medical, beauty and grooming, vitamins and supplements, fitness, food and beverage, and pet markets.
+ 1 more risk
Imperfect balance sheet and overvalued.
Share Price & News
How has Eviana Health's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EVNN.F has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how EVNN.F performed against the US Chemicals industry.
Return vs Market: Insufficient data to determine how EVNN.F performed against the US Market.
Price Volatility Vs. Market
How volatile is Eviana Health's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Eviana Health undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate EVNN.F's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate EVNN.F's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: EVNN.F is unprofitable, so we can't compare its PE Ratio to the Chemicals industry average.
PE vs Market: EVNN.F is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EVNN.F's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EVNN.F is good value based on its PB Ratio (0.3x) compared to the US Chemicals industry average (1.5x).
How is Eviana Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Materials industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Eviana Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of EVNN.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Eviana Health's filings and announcements here.
- Explore growth companies in the Materials industry.
How has Eviana Health performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: EVNN.F is currently unprofitable.
Growing Profit Margin: EVNN.F is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if EVNN.F's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare EVNN.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EVNN.F is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-11.3%).
Return on Equity
High ROE: EVNN.F has a negative Return on Equity (-87.79%), as it is currently unprofitable.
How is Eviana Health's financial position?
Financial Position Analysis
Short Term Liabilities: EVNN.F's short term assets (CA$11.1M) exceed its short term liabilities (CA$2.3M).
Long Term Liabilities: EVNN.F's short term assets (CA$11.1M) exceed its long term liabilities (CA$8.0M).
Debt to Equity History and Analysis
Debt Level: EVNN.F's debt to equity ratio (170%) is considered high.
Reducing Debt: Insufficient data to determine if EVNN.F's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if EVNN.F has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if EVNN.F has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Eviana Health's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EVNN.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate EVNN.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EVNN.F's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EVNN.F's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EVNN.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. Avram Adizes, Ph.D., P.E., serves as the Chief Technology Officer of Phoenix Capital Partners Inc. Dr. Adizes is responsible for Technology assessment and evaluation. Dr. Adizes serves as Chairman and ...
CEO Compensation Analysis
Compensation vs Market: Avram's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD614.05K).
Compensation vs Earnings: Insufficient data to compare Avram's compensation with company performance.
|Chairman of the Board & CEO||2.67yrs||CA$120.00k||7.49% CA$83.4k|
|CFO & Director||6.83yrs||CA$60.00k||0.92% CA$10.3k|
|Member of Advisory Board||1.75yrs||no data||no data|
Experienced Board: EVNN.F's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.9%.
Eviana Health Corporation's company bio, employee growth, exchange listings and data sources
- Name: Eviana Health Corporation
- Ticker: EVNN.F
- Exchange: OTCPK
- Founded: 2011
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: CA$1.553m
- Listing Market Cap: CA$1.113m
- Shares outstanding: 23.90m
- Website: https://eviana.ca
- Eviana Health Corporation
- 5728 East Boulevard
- British Columbia
- V6M 4M4
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|EHC||CNSX (Canadian National Stock Exchange)||Yes||Common Shares||CA||CAD||Sep 2017|
|EVNN.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Sep 2017|
|1CP||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Sep 2017|
Eviana Health Corporation produces and sells cannabinoid products from natural hemp strains of cannabis sativa for medical, beauty and grooming, vitamins and supplements, fitness, food and beverage, and pet markets. It is also involved in the growing of industrial hemp and extraction of cannabidiol. The company was formerly known as C&C Cosmeceuticals Corp. and changed its name to Eviana Health Corporation in May 2017. Eviana Health Corporation was incorporated in 2011 and is headquartered in Vancouver, Canada.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/10 01:17|
|End of Day Share Price||2020/02/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.